Title: NIHR London In Vitro Diagnostics Co-operative (short name: NIHR London IVD Co-operative)
Funder: Department of Health and Social Care

Abstract: NIHR-MIC London Diagnostics will work closely with patients, doctors, scientists and industry to provide high quality evidence for diagnostic tests and devices building on the successes of our NIHR-DEC London. We have developed a &ldquo;systems approach to evaluate diagnostic innovations&rdquo;. This approach allows for the generation of comprehensive evidence by considering the entire patient pathway and all parties involved in the decision-making process. Methods are tailored to fit the goals and stages of the work in order to enhance the innovation pathway to clinical practice in line with the recent government report &ldquo;Accelerated Access Review&rdquo;. As DEC, we have worked with 107 companies and received &pound;7.7M. As a partnership between Imperial College Healthcare NHS Trust, Imperial College London and the Royal Brompton and Harefield NHS Foundation Trust, the NIHR MIC London Diagnostics places patients and the NHS at the centre of innovation and the generation of evidence. Our proposed work is based on three core themes: clinical studies, method development and technology. The clinical theme intentionally includes specialities where unmet needs have been identified (Gastrointestinal, Cancer, Haematology, Infectious Diseases, Respiratory, Critical Care, Trauma and Primary care). We will continue to develop methods to support a rapid cycle evidence generation and human factors that govern the use of diagnostics in clinical practice. We will utilise existing expertise within the Departments of Engineering, Chemistry and Materials to extend our support to industry and take scientific innovations to the clinical setting. Industry, in particular small and medium size enterprises, are at the heart of our vision, objectives and work. We have strategic partnerships to share our methodology with Imperial and Royal Marsden NIHR Biomedical Research Centres and potential future MICs (MindTech (Nottingham), Brain Injury (Cambridge), Enteric (Royal London), Trauma Management (Birmingham) and WoundTech (Bradford). We also have joint initiatives with the National Institute for Health and Care Excellence (NICE), Medicines and Healthcare Products Regulatory Agency (MHRA), Imperial and Oxford Academic Healthcare Science Networks (AHSN) and selected academic institutions across the UK. We will continue to work closely with the NIHR Patient Safety Translational Research Centre (PSTRC), the NIHR Collaboration for Leadership in Applied Health Research and Care (CLAHRC) Northwest London and other NIHR infrastructure. Through our existing experience and partnership with the British In-Vitro Diagnostics Association (BIVDA) we will widen our network of industrial collaborators. We will also build frameworks to encourage patient and public involvement in this work and to facilitate the transfer knowledge throughout the NHS.

Lay abstract: NIHR-MIC London Diagnostics will work closely with patients, doctors, scientists and industry to provide high quality evidence for diagnostic tests and devices building on the successes of our NIHR-DEC London. We have developed a &ldquo;systems approach to evaluate diagnostic innovations&rdquo;. This approach allows for the generation of comprehensive evidence by considering the entire patient pathway and all parties involved in the decision-making process. Methods are tailored to fit the goals and stages of the work in order to enhance the innovation pathway to clinical practice in line with the recent government report &ldquo;Accelerated Access Review&rdquo;. As DEC, we have worked with 107 companies and received &pound;7.7M. As a partnership between Imperial College Healthcare NHS Trust, Imperial College London and the Royal Brompton and Harefield NHS Foundation Trust, the NIHR MIC London Diagnostics places patients and the NHS at the centre of innovation and the generation of evidence. Our proposed work is based on three core themes: clinical studies, method development and technology. The clinical theme intentionally includes specialities where unmet needs have been identified (Gastrointestinal, Cancer, Haematology, Infectious Diseases, Respiratory, Critical Care, Trauma and Primary care). We will continue to develop methods to support a rapid cycle evidence generation and human factors that govern the use of diagnostics in clinical practice. We will utilise existing expertise within the Departments of Engineering, Chemistry and Materials to extend our support to industry and take scientific innovations to the clinical setting. Industry, in particular small and medium size enterprises, are at the heart of our vision, objectives and work. We have strategic partnerships to share our methodology with Imperial and Royal Marsden NIHR Biomedical Research Centres and potential future MICs (MindTech (Nottingham), Brain Injury (Cambridge), Enteric (Royal London), Trauma Management (Birmingham) and WoundTech (Bradford). We also have joint initiatives with the National Institute for Health and Care Excellence (NICE), Medicines and Healthcare Products Regulatory Agency (MHRA), Imperial and Oxford Academic Healthcare Science Networks (AHSN) and selected academic institutions across the UK. We will continue to work closely with the NIHR Patient Safety Translational Research Centre (PSTRC), the NIHR Collaboration for Leadership in Applied Health Research and Care (CLAHRC) Northwest London and other NIHR infrastructure. Through our existing experience and partnership with the British In-Vitro Diagnostics Association (BIVDA) we will widen our network of industrial collaborators. We will also build frameworks to encourage patient and public involvement in this work and to facilitate the transfer knowledge throughout the NHS.

Research activity codes: 4.5 RESOURCES AND INFRASTRUCTURE (DETECTION)
Health categories: CANCER AND NEOPLASMS;METABOLIC AND ENDOCRINE